Package 0002-7797-61

{"route": ["SUBCUTANEOUS"], "spl_id": "44cd7f6e-d6f3-4073-9c40-46b3bb4b6091", "openfda": {"nui": ["N0000193985", "N0000193986"], "unii": ["U9JLP7V031"], "rxcui": ["2693784", "2693791", "2693903", "2693907"], "spl_set_id": ["7a774ea2-acde-4aaa-9a8f-ccba5a5b1d5f"], "pharm_class_epc": ["Interleukin-13 Antagonist [EPC]"], "pharm_class_moa": ["Interleukin-13 Antagonists [MoA]"], "manufacturer_name": ["Eli Lilly and Company"], "is_original_packager": [true]}, "finished": true, "packaging": [{"sample": false, "description": "1 SYRINGE in 1 CARTON (0002-7797-11)  / 2 mL in 1 SYRINGE (0002-7797-01)", "package_ndc": "0002-7797-11", "marketing_start_date": "20240913"}, {"sample": true, "description": "1 SYRINGE in 1 CARTON (0002-7797-61)  / 2 mL in 1 SYRINGE", "package_ndc": "0002-7797-61", "marketing_start_date": "20240913"}], "brand_name": "EBGLYSS", "product_id": "0002-7797_44cd7f6e-d6f3-4073-9c40-46b3bb4b6091", "dosage_form": "INJECTION, SOLUTION", "pharm_class": ["Interleukin-13 Antagonist [EPC]", "Interleukin-13 Antagonists [MoA]"], "product_ndc": "0002-7797", "generic_name": "lebrikizumab-lbkz", "labeler_name": "Eli Lilly and Company", "product_type": "HUMAN PRESCRIPTION DRUG", "brand_name_base": "EBGLYSS", "active_ingredients": [{"name": "LEBRIKIZUMAB", "strength": "250 mg/2mL"}], "application_number": "BLA761306", "marketing_category": "BLA", "marketing_start_date": "20240913", "listing_expiration_date": "20261231"}